Skip to main content
Jula Inrig, MD, Nephrology, Orange, CA

JulaInrigMDMHS, FASN

Nephrology Orange, CA

Global Head Renal Center of Excellence, IQVIA; Associate Professor of Medicine, Dept of Medicine, Division of Nephrology, UC Irvine and Duke University

Dr. Inrig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Inrig's full profile

Already have an account?

  • Office

    101 The City Dr S
    Orange, CA 92868
    Phone+1 714-880-7812

Education & Training

  • Duke University
    Duke UniversityMHS, Clinical Research, 2004 - 2006
  • Duke University Hospital
    Duke University HospitalFellowship, Nephrology, 2003 - 2005
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2000 - 2003
  • Loma Linda University School of Medicine
    Loma Linda University School of MedicineClass of 2000
  • California State University, Sacramento
    California State University, SacramentoB.A., Biochemistry, Magna Cum Laude, 1992 - 1996

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2014 - 2026
  • TX State Medical License
    TX State Medical License 2008 - 2016
  • NC State Medical License
    NC State Medical License 2000 - 2009
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
  • Who's Who in America Marquis, 2008
  • R. Snyderman Clinical Research Fellowship Grant Award R. Snyderman Clinical Research Fellowship Grant, 2006
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Intradialytic blood pressure variability is associated with increased all-cause and cardiovascular mortality  
    Flythe JE, Inrig JK, Shafi T, Chang TI, Cape K, Dinesh K, Kunaparaju S, Brunelli SM, Am J Kidney Dis, 3/6/2013
  • Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.  
    McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Califf RM, Patel UD, Singh AK, Szczech LA, Am J Nephrol, 1/1/2013
  • Practice Pointers: Hypertension and blood pressure goals in the dialysis unit.  
    Inrig JK and Griffiths K, ASN Kidney News, 1/1/2013
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Desing and Rationale for a randomized, double-blind, placebo-controlled phase 2 study to evaluate efficacy and safety of nalfurafine (MT_9938) for treatment of uremic ...
    Yosipovich G, Inrig J, Mayo Marlyn, Block G, Takei K, Lieberman B, Palumbo JM, American Society of Nephrology Annual Meeting, San Diego, CA, 1/1/2012
  • Systematic Analysis of Nephrology Studies in ClinicalTrials.gov.
    Inrig JK, Califf RM, Tasneem A, Chiswell K, Patel UD, American Society of Nephrology Annual Meeting, San Diego, CA, 1/1/2012
  • Dialysate Sodium Promotes Endothelial Cell Dysfunction in Patients with Intradialytic Hypertension.
    Kim C, Van Buren P, Klimas N, Inrig JK, American Society of Nephrology Annual Meeting, San Diego, CA, 1/1/2012
  • Join now to see all

Lectures

  • Topic: Blood Pressure, Salt and Water in Hemodialysis Patients 
    10/10/2013
  • The Effect Of Dialysate Sodium On Intradialytic Hypertension. 
    San Francisco, CA - 4/28/2013
  • Strategies to Optimize Blood Pressure Management in Dialysis 
    4/19/2013
  • Join now to see all

Other

  • Blood Pressure with Epo 
    Inrig JK, Renal and Urology News, Jody A. Charnow
    11/1/2012
  • "Dialysis Data Shines Light on Clinic Disparities Detailed information on North Texas dialysis clinic death rates." 
    Inrig JK, NBC Interview with Ken Kalthoff
    http://www.nbcdfw.com/news/health/Dialysis-Data-Shines-Light-on-Clinic-Disparities-147838245.html
    4/17/2012
  • Hot issues to watch for in 2011 
    Inrig JK, Saggi S, Weiner D, Shaffer R, Mehrotra on behalf of the ASN Dialysis Advisory Group. Bundled Payments, ASN Kidney News
    1/1/2011
  • Join now to see all

Press Mentions

  • The Sudden Progress in Rare Kidney Disease Is Built on Years of Dedication
    The Sudden Progress in Rare Kidney Disease Is Built on Years of DedicationOctober 14th, 2024
  • Travere’s FSGS Therapy Trial Fails to Meet Primary Efficacy Endpoint
    Travere’s FSGS Therapy Trial Fails to Meet Primary Efficacy EndpointMay 2nd, 2023
  • Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
    Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisMay 2nd, 2023
  • Join now to see all

Committees

  • Inaugural Board of Directors, Kidney Health Initiative 2013 - 2017
  • Member, KDOQI Hemodialysis Adequacy Clinical Practice Guidelines Update Work Group, National Kidney Foundation 2012 - 2015

Professional Memberships